1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 2: Clinical presentation of 507 patients with cerebral AVMs
TDBS (No.) (%) No TDBS (No.) (%) Multinomial Logistic Regression
P Value Odds Ratio
All patients (n = 535) 39 496 
Previous AVM treatment 7 (18) 21 (4) 
Enrolled patients (n = 507) 32 475 
    Male 10 (31) 260 (55) .004 3.433
    Hemorrhage 9 (28) 225 (47) .3 0.968
    Seizures 8 (25) 79 (17) .4 1.672
    Headache 7 (22) 44 (9) .06 3.024
    Other 8 (25) 127 (27) 
Age (U test) (yr) 
    Mean 46 ± 14 40 ± 18 .07 
    Range 13–75 2–87

	TDBS (No.) (%)	No TDBS (No.) (%)	Multinomial Logistic Regression
	TDBS (No.) (%)	No TDBS (No.) (%)	P Value	Odds Ratio
All patients (n = 535)	39	496
Previous AVM treatment	7 (18)	21 (4)
Enrolled patients (n = 507)	32	475
Male	10 (31)	260 (55)	.004	3.433
Hemorrhage	9 (28)	225 (47)	.3	0.968
Seizures	8 (25)	79 (17)	.4	1.672
Headache	7 (22)	44 (9)	.06	3.024
Other	8 (25)	127 (27)
Age (U test) (yr)
Mean	46 ± 14	40 ± 18	.07
Range	13–75	2–87